10-Q · May 6, 2026
Repligen's Q1 2026 results showed a strong performance with revenue of $194.3 million, marking a 14.8% YoY increase, and an EPS of $0.48, surpassing estimates of $0.38. The company's growth was driven by robust product…
Earnings analysis · 10-Q
RGEN earnings analysis
Filed October 30, 2026 · Our reading of the company's report
The latest report
Repligen’s third-quarter results were favorable: revenue increased to $209.314 million from $204 million in the prior quarter and $189 million a year earlier, while diluted EPS rose to $0.53 from $0.09 and $0.26,…
Read full summary
Repligen’s third-quarter results were favorable: revenue increased to $209.314 million from $204 million in the prior quarter and $189 million a year earlier, while diluted EPS rose to $0.53 from $0.09 and $0.26, respectively. However, the filing does not provide quantitative guidance, and current gross margin, operating margin, cash flow, balance-sheet, and segment data were not disclosed in the supplied filing text. The principal negatives are unresolved material weaknesses as of September 30, 2026 and new execution and market-size risks related to the BioLife acquisition.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.53
What stood out
-
Revenue accelerated sequentially and year over year
Third-quarter revenue was $209.314 million, up from $204 million in 2026 Q2 and $189 million in 2025 Q3, representing sequential growth of approximately 2.6% and year-over-year growth of approximately 10.8%.
-
EPS rebounded sharply
Diluted EPS was $0.53 versus $0.09 in 2026 Q2 and $0.26 in 2025 Q3, an increase of $0.44 sequentially and $0.27 year over year.
-
Beat revenue and EPS estimates
Revenue exceeded the $206.726 million consensus estimate by approximately $2.588 million, while EPS of $0.53 exceeded the $0.46 estimate by $0.07.
-
Internal-control remediation is underway
Management reported that it performed remediation activities during the nine months ended September 30, 2026, including engaging third-party experts, redesigning controls, and implementing software tools for control monitoring.
-
Market-risk exposure unchanged
The company stated that there were no material changes to market-risk exposures since December 31, 2025.
What to watch
-
Material weaknesses remain unresolved
As of September 30, 2026, management had not remediated the previously reported material weaknesses involving IT general controls and business-process controls for inventory valuation and the financial-statement close process.
-
BioLife integration execution risk
The company added acquisition-related risks tied to BioLife, including the possibility that integration efforts could require significant management attention and resources, cause delays or costs, or prevent realization of anticipated synergies.
-
Cell-therapy market assumptions may fail
The company warned that its assumptions about the size and trajectory of the cell-therapy market and BioLife’s market position may be incorrect, and that the transaction’s anticipated financial impact and revenue growth may not be realized.
Management's outlook
The 10-Q does not provide quantitative revenue or EPS guidance; no change to prior outlook is disclosed.
Earlier filings 4
10-K · February 26, 2026
Repligen reported a recovery in profitability through 2025 with Q4 revenue of $197,913,000 and improving margins (Q4 2025 gross margin 52.5%, operating margin 9.0%) after a weak Q4 2024. The company is executing a…
10-Q · August 7, 2025
Repligen reported a strong Q2 2025 quarter with revenue of $182,366,000 (Q2 2024: $158,839,000), driving operating income of $13,896,000 (Q2 2024: $5,469,000) and diluted EPS of $0.26 (Q2 2024: $0.10). Management…
10-Q · April 29, 2025
Repligen reported a stronger Q1 2025 with revenue rising to $169.172M from $153.182M a year ago (+$15.99M, +10.4%), gross margin expanding to ~53.7% (COGS $78.415M) and operating income rising to $6.578M (3.9% op…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.